[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR065580A1 - Mejoras en composiciones medicinales o relativas a las mismas - Google Patents

Mejoras en composiciones medicinales o relativas a las mismas

Info

Publication number
AR065580A1
AR065580A1 ARP080100881A ARP080100881A AR065580A1 AR 065580 A1 AR065580 A1 AR 065580A1 AR P080100881 A ARP080100881 A AR P080100881A AR P080100881 A ARP080100881 A AR P080100881A AR 065580 A1 AR065580 A1 AR 065580A1
Authority
AR
Argentina
Prior art keywords
buprenorphine
naltrexone
same
dosage form
medicinal compositions
Prior art date
Application number
ARP080100881A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065580(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of AR065580A1 publication Critical patent/AR065580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion analgésica, en una forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la dermis o mucosa, donde dicha composicion comprende buprenorfina y una cantidad de naltrexonatal que la relacion en peso de buprenorfina a naltrexona administrada o que alcanzo el plasma de un paciente se encuentra en el rango entre 100: 1 y 5000:1. La accion analgésica de buprenorfina es potenciada por la baja dosis de naltrexona. Unmétodo de tratamiento del dolor y el uso de buprenorfina y naltrexona para la elaboracion de un medicamento.
ARP080100881A 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas AR065580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703966A GB2447014A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone

Publications (1)

Publication Number Publication Date
AR065580A1 true AR065580A1 (es) 2009-06-17

Family

ID=37965733

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100881A AR065580A1 (es) 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas

Country Status (21)

Country Link
US (1) US8912211B2 (es)
EP (1) EP2125019B1 (es)
JP (1) JP5577101B2 (es)
KR (1) KR20090115861A (es)
CN (1) CN101622014A (es)
AR (1) AR065580A1 (es)
AU (1) AU2008220620A1 (es)
BR (1) BRPI0807902A2 (es)
CA (1) CA2678481C (es)
CL (1) CL2008000608A1 (es)
DK (1) DK2125019T3 (es)
ES (1) ES2475734T3 (es)
GB (1) GB2447014A (es)
HR (1) HRP20140592T1 (es)
MX (1) MX2009009132A (es)
PE (1) PE20081799A1 (es)
PL (1) PL2125019T3 (es)
PT (1) PT2125019E (es)
TW (1) TW200836737A (es)
WO (1) WO2008104735A1 (es)
ZA (1) ZA200905689B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205081B2 (en) 2010-04-29 2015-12-08 Allodynic Therapeutics, Llc Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US9095548B2 (en) 2010-04-29 2015-08-04 Allodynic Therapeutics, Llc Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
MX2013003354A (es) * 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
JP2016512561A (ja) * 2013-03-13 2016-04-28 アロディニック セラピューティクス リミテッド ライアビリティ カンパニー オピオイド／トール様受容体４アンタゴニスト、そのデキストロエナンチオマーを含む、痛みを軽減するための組成物、及びそのための使用方法
ES2703623T3 (es) * 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US20180147201A1 (en) 2016-10-31 2018-05-31 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US11752143B2 (en) 2020-12-31 2023-09-12 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572149A (en) * 1896-12-01 Tobacco-cutting machine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
PL341309A1 (en) * 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
SI2517710T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
US8912211B2 (en) 2014-12-16
KR20090115861A (ko) 2009-11-09
GB0703966D0 (en) 2007-04-11
EP2125019A1 (en) 2009-12-02
AU2008220620A1 (en) 2008-09-04
PL2125019T3 (pl) 2014-08-29
CN101622014A (zh) 2010-01-06
DK2125019T3 (da) 2014-06-30
JP2010520183A (ja) 2010-06-10
TW200836737A (en) 2008-09-16
EP2125019B1 (en) 2014-04-09
CA2678481A1 (en) 2008-09-04
JP5577101B2 (ja) 2014-08-20
PT2125019E (pt) 2014-07-11
CL2008000608A1 (es) 2008-10-03
MX2009009132A (es) 2009-09-03
WO2008104735A1 (en) 2008-09-04
HRP20140592T1 (hr) 2014-09-12
ZA200905689B (en) 2010-10-27
BRPI0807902A2 (pt) 2014-06-17
ES2475734T3 (es) 2014-07-11
GB2447014A (en) 2008-09-03
CA2678481C (en) 2014-11-18
US20100120812A1 (en) 2010-05-13
PE20081799A1 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR031682A1 (es) Composiciones farmaceuticas
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2010520186A5 (es)
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
WO2012007159A3 (en) Novel gastro-retentive dosage forms
AR063782A1 (es) Parche y metodo transdermico para emesis
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
BRPI0409380A (pt) composições farmacêuticas
JP2010520184A5 (es)
BR112014004339A2 (pt) suspensão oral
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina

Legal Events

Date Code Title Description
FB Suspension of granting procedure